News | March 10, 2026
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
The collaboration will leverage Medi Assist’s proprietary technology to streamline claims processing, enhance transparency, and deliver smarter health benefits to policyholders in the region
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
Subscribe To Our Newsletter & Stay Updated
